Vaccinex Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 12, 2019 08:00 ET
|
Vaccinex, Inc.
Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected by the end of 2019 Updated interim data from the...
Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 09, 2019 08:02 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Nov. 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Plus Therapeutics To Report Fiscal 2019 Third Quarter Financial Results and Corporate Update on November 14, 2019
November 04, 2019 07:00 ET
|
Plus Therapeutics, Inc.
AUSTIN, Texas, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced that it will report its Fiscal 2019 Third Quarter financial results after the...
Telix Pharmaceuticals and AusHealth to Partner on Novel Therapeutics for Lung, Ovarian Cancer
October 29, 2019 19:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and ADELAIDE, Australia, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) has today announced that Telix and AusHealth have entered into a collaboration...
Plus Therapeutics Receives $4.6MM Reimbursement Payment
October 15, 2019 09:20 ET
|
Plus Therapeutics, Inc.
AUSTIN, Texas, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced that it received a $4.6 million payment from the U.S. Department of Health and...
Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer in Podium and Poster Presentations at the Fifth International Cancer lmmunotherapy Conference in Paris, France
September 27, 2019 06:05 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Lung Ambition Alliance unveils new initiatives to address lung cancer survival at the World Conference on Lung Cancer
September 07, 2019 10:00 ET
|
Lung Ambition Alliance
New grants program to support local initiatives driven by patient organizations that have the potential to transform patient care Series of interactive and educational exhibits at the congress to...
VisionGate Announces an Exclusive Global License, Manufacturing and Supply Agreement for Iloprost, VisionGate’s Phase 2 Oral Lung Cancer Interception Drug
August 22, 2019 08:00 ET
|
VisionGate, Inc.
Seattle, WA, Aug. 22, 2019 (GLOBE NEWSWIRE) -- VisionGate, Inc., a clinical stage oncology pharmaceutical and diagnostics company, announces that it has finalized an exclusive worldwide license...
Plus Therapeutics Reports Q2 2019 Financial and Business Results
August 15, 2019 19:21 ET
|
Plus Therapeutics, Inc.
AUSTIN, Texas, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced Q2 2019 financial results and provided updates on corporate activities. Q2...
Lung Cancer Foundation of America introduces Hope With Answers℠: videos by patients, for patients and their families
August 01, 2019 17:18 ET
|
Lung Cancer Foundation of America
Los Angeles, Aug. 01, 2019 (GLOBE NEWSWIRE) -- An innovative new project by Lung Cancer Foundation of America (LCFA) is turning the tables on the traditional doctor-patient relationship by having...